Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis completes acquisition of Regulus Therapeutics
09:13am, Wednesday, 25'th Jun 2025
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of com
Novartis: A SWAN Worth Owning
07:00am, Wednesday, 25'th Jun 2025
Novartis AG could be a qualitative investment with a margin of safety. The drugmaker arguably has the balanced commercial drug portfolio and drug pipeline needed to sustain growth in the years ahead.
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
10:11am, Monday, 16'th Jun 2025
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
09:56am, Monday, 16'th Jun 2025
As markets reel under the Israel-Iran conflict, NVS, ENSG, MTZ, BILI and STRL stocks offer a safer path through volatility.
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
10:15am, Friday, 13'th Jun 2025
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
02:25pm, Thursday, 12'th Jun 2025
Novartis AG NVS on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysma
Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult pa
Top Cancer Stocks to Supercharge Your 2025 Portfolio
11:26am, Tuesday, 10'th Jun 2025
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
10:56am, Monday, 09'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis (NVS) Could Be a Great Choice
12:51pm, Friday, 06'th Jun 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
2 Dividend Growth Stocks to Buy and Hold Forever
06:45am, Friday, 06'th Jun 2025
When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even wo
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
03:20am, Monday, 02'nd Jun 2025
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
02:04am, Monday, 02'nd Jun 2025
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus horm
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
11:16am, Friday, 30'th May 2025
NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.
